Tasman Oncology Research

Southport, Queensland 4216

6 studies enrolling now · 13 studies all time

What they study most

Abiraterone Acetate, Adenoid Cystic Carcinoma, Advanced Solid Tumor, Advanced Solid Tumors, Androgens, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Bile Duct Cancer, Bladder Cancer, Breast Neoplasms, Carcinoma in Situ, Carcinoma, Non-Small-Cell Lung

Studies at this site

• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer — Recruiting now
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Recruiting now
• A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors — Recruiting now
• A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 — Recruiting now
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. — Recruiting now
• A Study of DM001 in Patients With Advanced Solid Tumors — Recruiting now
• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) — Running, not enrolling
• A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors — Stopped early
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling
• Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). — Completed
• Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611 — Completed
• CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) — Completed